Trials / Completed
CompletedNCT01107054
A Study to Investigate the Effects of PF00610335 on the QT/QTC Interval in Healthy Volunteers
A Double Blind, Randomized, Multiple Dose, Placebo And Active Controlled 4-Way Crossover Study To Investigate The Effects Of Inhaled PF-00610355 On QT/QTC Interval In Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
A study to determine the cardiovascular effects of PF00610335 in healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-00610355 | An orally inhaled dose of PF-00610355 450 µg on days 1 to 4 |
| DRUG | PF-00610355 | An orally inhaled dose of PF-00610355 1200 µg on days 1 to 4 |
| DRUG | moxifloxacin | A single oral dose of moxifloxacin 400 mg on Day 4. |
| DRUG | placebo | A single oral dose of non-matched placebo on Day 4. |
Timeline
- Start date
- 2010-06-01
- Primary completion
- 2010-09-01
- Completion
- 2010-12-01
- First posted
- 2010-04-20
- Last updated
- 2011-01-13
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT01107054. Inclusion in this directory is not an endorsement.